BACKGROUND INFORMATION ON THE PROCEDURE 
1.  Submission of the dossier 
The  applicant,  Takeda  Global  R&D  Centre  (Europe)  Ltd.,  submitted  on  28  February  2005  an 
application for Marketing Authorisation to the European Medicines Agency (EMEA) for Competact, 
through  the  centralised  procedure  under  Article  3(2)(b)  of  Regulation  (EC)  No  726/2004.  The 
eligibility  to  the  centralised  procedure  was  agreed  upon  by  the  EMEA/CHMP  on  20  January  2005 
(Part  B  status,  Annex  to  Council  Regulation  (EEC)  No  2309/93).  The  eligibility  to  the  centralised 
procedure under Article 3(2)(b) of Regulation (EC) No 726/2004 was based on the consideration of 
this fixed combination of active substances as a new active substance. 
The legal basis for this application refers to:  
Article 8.3 of Directive 2001/83/EC, as amended - complete and independent application 
The applicant applied for the following indication: 
Indicated  in  the  treatment  of  type  2  diabetes  mellitus  patients,  particularly  overweight  patients,  who 
are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin 
alone. 
Licensing status: 
The product was not licensed in any country at the time of submission of the application. 
The Rapporteur and Co-Rapporteur appointed by the CHMP were: 
Rapporteur:  Dr. Patrick Salmon (IRL) 
Co-Rapporteur:  Dr. Concepción Prieto Yerro (ES) 
2.  Steps taken for the assessment of the product 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
The application was received by the EMEA on 28 February 2005. 
The procedure started on 28 March 2005. 
The Rapporteur's first Assessment Report was circulated to all CHMP members on 8 June 2005. 
The  Co-Rapporteur's  first  Assessment  Report  was  circulated  to  all  CHMP  members  on  
9 June 2005. 
During  the  meeting  on  25-28  July  2005,  the  CHMP  agreed  on  the  consolidated  List  of 
Questions to be sent to the applicant. The final consolidated List of Questions was sent to the 
applicant on 28 July 2005. 
The  applicant  submitted  the  responses  to  the  CHMP  consolidated  List  of  Questions  on  
8 December 2005. 
The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the List 
of Questions to all CHMP members on 23 January 2006. 
During the CHMP meeting on 20-23 February 2006, the CHMP agreed on a List of Outstanding 
Issues to be addressed in writing and in an oral explanation by the applicant. 
The applicant submitted the responses to the List of Outstanding Issues on 17 March 2006. 
The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the List 
of Outstanding Issues to all CHMP members on 7 April 2006. 
The  applicant  submitted  a  letter  requesting  the  withdrawal  of  one  product  strength  on  
25 April 2006. 
The  Rapporteurs  circulated  the  Updated  Overview  of  the  Joint  Assessment  Report  on  the 
applicant’s responses to the List of Outstanding Issues to all CHMP members on 15 May 2006. 
During  the  meeting  on  29  May  to  1  June  2006,  the  CHMP,  in  the  light  of  the  overall  data 
submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for 
granting a Marketing Authorisation to Competact on 1 June 2006. The applicant provided the 
©EMEA 2006 
   Page 1/2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
• 
letter  of  undertaking  on  the  follow-up  measures  to  be  fulfilled  post-authorisation  within  two 
months from the granting of the market authorisation. 
The  CHMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decisions on 28 July 2006. 
                                                                                         ©EMEA 2006 
    Page 2/2 
 
 
